Haisco wins pediatric approval for remimazolam; shareholder pledges stock

Haisco Pharmaceutical Group Co., Ltd. announced its subsidiary, Shenyang Haisco Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration to expand the pediatric indication for remimazolam besylate for injection (Haisunol).

This approval permits its use for induction and maintenance of general anesthesia in children and adolescents, alongside revised safety information. The drug, initially approved in December 2020, already holds registrations for various adult anesthesia and sedation indications and is currently under FDA review.

In a separate announcement, Haisco disclosed that Ms. Fan Xiulian, a shareholder, pledged 4.9 million shares (representing 2.25% of her holdings and 0.44% of the company's total share capital) to Guojin Securities Asset Management Co., Ltd. for her own production and operation needs. The pledge commenced on September 19, 2025.

Following this transaction, Ms. Fan Xiulian's cumulative pledged shares amount to 5.101 million, representing 23.47% of her total holdings. Including Ms. Yang Fei, the total pledged shares for both shareholders stand at 5.101 million, accounting for 19.64% of their combined holdings and 4.55% of the company's total share capital.